{
  "retracted": false,
  "timestamp": 1590969600000,
  "updates": [
    {
      "timestamp": 1592827849019,
      "identifier": {
        "doi": "10.1136/jitc-2020-000798corr1"
      },
      "type": "correction"
    }
  ],
  "identifier": {
    "doi": "10.1136/jitc-2020-000798"
  },
  "journal": "Journal for ImmunoTherapy of Cancer",
  "publisher": "BMJ",
  "title": "Correction: Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial"
}
